Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book PDF full book. Access full book title Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book by Daniel W. Lee. Download full books in PDF and EPUB format.
Author: Daniel W. Lee Publisher: Elsevier Health Sciences ISBN: 0323755976 Category : Medical Languages : en Pages : 246
Book Description
From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.
Author: Daniel W. Lee Publisher: Elsevier Health Sciences ISBN: 0323755976 Category : Medical Languages : en Pages : 246
Book Description
From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.
Author: Dr. Hakim Saboowala Publisher: Dr.Hakim Saboowala ISBN: Category : Medical Languages : en Pages :
Book Description
Part I- Understanding Cancer Immunotherapy: A brief Review. Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function. Immunotherapy may work by: Stopping or slowing the growth of cancer cells Stopping cancer from spreading to other parts of the body Helping the immune system work better at destroying cancer cells There are several types of immunotherapy, including: Monoclonal antibodies and tumor-agnostic therapies Non-specific immunotherapies Oncolytic virus therapy T-cell therapy Cancer vaccines Part II- “What is Chimeric Antigen Receptor (CAR) T- Cell Therapy?” An Emerging Cancer Treatment Modality. Chimeric antigen receptor (CAR) T-cell therapy is an emerging cancer treatment modality in which the patients’ own immune cells are collected, genetically engineered to recognize a tumor-related target, expanded in vitro, and then reinfused to produce responses and prevent progression in a variety of malignancies (ie, adoptive cell transfer) Several types of adoptive cell transfer(ACT) are under investigation, but CAR T-cell therapy is the first to enter clinical practice. Like other technologies, CAR-T cell therapy has undergone a long development process in the past. Chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. At present, CAR-T cell therapy is developing rapidly, and many clinical trials have been established on a global scale, which has great commercial potential. I have endeavored to compile this E- Booklet into Two Parts i.e. Part I & Part II for better understanding of Chimeric antigen receptor (CAR) T-cell therapy, an emerging cancer treatment modality. In Part I, an effort has been made to describe Cancer Immunotherapy briefly whereas in Part II know about of CAR T-Cell Therapy-the first to enter clinical practice- has been embodied. Further it is attempted to describe toxicity of CAR-T cell therapy briefly and future development and opportunities for immunotherapy. …Dr. H. K. Saboowala. M.B.(Bom) .M.R.S.H.(London)
Author: National Academies Of Sciences Engineeri Publisher: National Academies Press ISBN: 9780309684002 Category : Medical Languages : en Pages :
Book Description
Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer.
Author: Rishabha Malviya Publisher: Springer Nature ISBN: 9811997861 Category : Science Languages : en Pages : 949
Book Description
This book highlights the role of Biomedical Engineering (BME) used in diagnosis (e.g., body scanners) and treatment (radiation therapy and minimal access surgery in order to prevent various diseases). In recent years, an important progress has been made in the expansion of biomedical microdevices which has a major role in diagnosis and therapy of cancer. When fighting cancer, efficacy and speed are of the utmost importance. A recently developed microfluidic chip has enabled a breakthrough in testing the efficacy of specialized cancer drugs. Effective cancer-targeting therapies will require both passive and active targeting strategies and a thorough understanding of physiologic barriers to targeted drug delivery. Targeted cancer treatments in development and the new combinatorial approaches show promise for improving targeted anticancer drug delivery and improving treatment outcomes. This book discusses the advancements and innovations in the field of BME that improve the diagnosis and treatment of cancer. This book is focused on bioengineering approaches to improve targeted delivery for cancer therapeutics, which include particles, targeting moieties, and stimuli-responsive drug release mechanisms. This book is a useful resource for students, researchers, and professionals in BME and medicine.
Author: Wilkes Publisher: Jones & Bartlett Learning ISBN: 1284117189 Category : Medical Languages : en Pages : 1660
Book Description
Written especially for nurses caring for patients with cancer, the 2017 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2017 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs. New drugs include: alectin
Author: PATHAN AZHER KHAN Publisher: Pristyn Research Solutions ISBN: 8197170134 Category : Science Languages : en Pages : 54
Book Description
This book comprehensively examines the landscape of immunotherapeutic modalities in cancer treatment, with a specific focus on Chimeric Antigen Receptor (CAR) T-cell therapy, immune checkpoint inhibitors, and other innovative approaches. The CAR T-cell therapy represents a groundbreaking approach wherein T-cells are genetically engineered to recognize and eradicate tumor cells expressing specific antigens. The book briefly discussed the clinical applications and challenges associated with CAR T-cell therapy, case studies highlighting its remarkable efficacy in malignancies, and emerging potential in solid tumors. Additionally, immune checkpoint inhibitors have transformed the treatment of various cancers by disrupting inhibitory signalling pathways and reinvigorating antitumor immune responses. This book explores the mechanisms, clinical efficacy, and challenges of immune checkpoint blockade, including strategies to overcome resistance and improve patient outcomes. Furthermore, it promises other innovative immunotherapeutic strategies, such as tumor vaccines, cytokine therapies, and adoptive cell transfer. Personalized Approaches emphasize their potential synergies and future directions in combination with existing modalities. Overall, this book provides insights into the evolving landscape of cancer immunotherapy, emphasizing the significant strides made in improving patient outcomes and the ongoing efforts to optimize treatment efficacy and durability while minimizing adverse effects.
Author: Daniel W. Lee
Author: Daniel W. Lee
Author: Dr. Hakim Saboowala
Author: National Academies Of Sciences Engineeri
Author: Rishabha Malviya
Author: Suzanne L. Walker
Author: Cristina Maccalli
Author: "Patrick" Peishun Shou
Author: Wilkes
Author: PATHAN AZHER KHAN
Author: Qian Ba